Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.40 |
| ▸ | PANK3 | Q9H999 | 2/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25105323 | 1.00 | KMT2A (0.49) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL30228730 | 1.00 | KMT2A (0.49) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL25105974 | 1.00 | KMT2A (0.49) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL30228895 | 0.97 | KMT2A (0.48) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL25104855 | 0.97 | KMT2A (0.48) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL30229011 | 0.97 | KMT2A (0.48) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL25105544 | 0.97 | KMT2A (0.48) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL25106016 | 0.97 | KMT2A (0.48) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL30228932 | 0.97 | KMT2A (0.48) | KMT2AMEN1SMN1; SMN2LMNAHTT | |
| SCHEMBL25105512 | 0.95 | KMT2A (0.47) | KMT2AMEN1SMN1; SMN2LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333397-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| WO-2023034836-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2023-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333397-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | KMT2A 3214/4885MEN1 3822/4885SMN1; SMN2 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.